顺铂联合生物反应调节剂腔内治疗恶性胸腹腔积液  

Intracavity Treatment with DDP and Biological Response Modifiers(BRM) for Malignant Pleural Effusions of Ascites

作　　者：胡卫东[1] 陈家宽[1] 高幼军[1] 

机构地区：[1]武汉大学中南医院肿瘤科,430071

出　　处：《实用癌症杂志》2001年第6期610-611,618,共3页The Practical Journal of Cancer

摘　　要：目的　探讨顺铂 (DDP)联合生物反应调节剂 (BRM )治疗恶性胸腹腔积液的疗效。方法　对 80例恶性胸腹腔积液患者 ,先抽尽积液 ,再腔内注射DDP +BRM (包括高聚金葡素、沙培林、胞必佳、白细胞介素 2 ) ,每周 1次 ,连续 2～ 3周 ,1个月后观察疗效。结果　DDP联合BRM治疗恶性胸腹腔积液总有效率为 85 .0 % ,不同的BRM与DDP联合运用 ,有效率无显著性差异 (P >0 .0 5 ) ,并发症少。结论　DDP联合BRM治疗恶性胸腹腔积液疗效肯定 ,是 1种较好的治疗方法。Objective To evalue the effect of intracavity treatment with DDP and BRM for malignant pleural effusions or ascites.Methods 80 cases of malignant body cavity effusions(60 cases of pleural effusion and 20 cases of ascites) were treated by intracavity injection of DDP and BRM,once a week,2～3 weeks.Results The effective rate of method was 85.0%.Intracavity with different BRM combining DDP had no significant different effect (P>0.05).Further more,the side effect and toxicity were slight.Conclusion The intracavity with DDP and BRM in the treatment malignant pleural effusions or ascites has a good and sure effect.

关 键 词：顺铂 生物反应调节剂 恶性胸腹腔积液 治疗 

分 类 号：R730.53[医药卫生—肿瘤]